208 related articles for article (PubMed ID: 23406835)
1. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.
Muraro E; Martorelli D; Dolcetti R
Hum Vaccin Immunother; 2013 May; 9(5):1078-83. PubMed ID: 23406835
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
5. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
7. Vaccination strategies in follicular lymphoma.
Kannan S; Neelapu SS
Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
[TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccines for human B-cell malignancies.
Inoges S; de Cerio AL; Soria E; Villanueva H; Pastor F; Bendandi M
Curr Pharm Des; 2010 Jan; 16(3):300-7. PubMed ID: 20109139
[TBL] [Abstract][Full Text] [Related]
9. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma.
Casales E; Martisova E; Villanueva H; de Cerio ALD; Inoges S; Silva-Pilipich N; Ballesteros-Briones MC; Aranda A; Bezunartea J; Bendandi M; Pastor F; Smerdou C
Sci Rep; 2021 Nov; 11(1):21427. PubMed ID: 34728659
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for lymphomas: idiotype vaccines and beyond.
Houot R; Levy R
Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
[TBL] [Abstract][Full Text] [Related]
11. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
12. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
13. Vaccine therapy for B-cell lymphomas: next-generation strategies.
Neelapu SS; Kwak LW
Hematology Am Soc Hematol Educ Program; 2007; ():243-9. PubMed ID: 18024636
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
15. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.
Bendandi M
Nat Rev Cancer; 2009 Sep; 9(9):675-81. PubMed ID: 19701243
[TBL] [Abstract][Full Text] [Related]
16. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
17. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
Armstrong AC; Cheadle EJ; Hawkins RE
BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
[TBL] [Abstract][Full Text] [Related]
18. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
Hurvitz SA; Timmerman JM
Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
[TBL] [Abstract][Full Text] [Related]
19. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
20. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]